Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized trial evaluating serial protein C levels in severe sepsis patients treated with variable doses of drotrecogin alfa (activated).
Shorr AF, Janes JM, Artigas A, Tenhunen J, Wyncoll DL, Mercier E, Francois B, Vincent JL, Vangerow B, Heiselman D, Leishman AG, Zhu YE, Reinhart K; RESPOND investigators. Shorr AF, et al. Among authors: vangerow b. Crit Care. 2010;14(6):R229. doi: 10.1186/cc9382. Epub 2010 Dec 21. Crit Care. 2010. PMID: 21176144 Free PMC article. Clinical Trial.
Drotrecogin alfa (activated) in severe sepsis.
Janes JM, Vangerow B, Costigan TM, Macias WL. Janes JM, et al. Among authors: vangerow b. Lancet Infect Dis. 2013 Feb;13(2):108-9. doi: 10.1016/S1473-3099(12)70309-2. Lancet Infect Dis. 2013. PMID: 23347626 No abstract available.
Drotrecogin alfa (activated) in adults with septic shock.
Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gårdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD; PROWESS-SHOCK Study Group. Ranieri VM, et al. Among authors: vangerow b. N Engl J Med. 2012 May 31;366(22):2055-64. doi: 10.1056/NEJMoa1202290. Epub 2012 May 22. N Engl J Med. 2012. PMID: 22616830 Free article. Clinical Trial.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators. Lincoff AM, et al. Among authors: vangerow b. N Engl J Med. 2017 May 18;376(20):1933-1942. doi: 10.1056/NEJMoa1609581. N Engl J Med. 2017. PMID: 28514624 Free article. Clinical Trial.
[Activated protein C and treatment of sepsis].
Høibraaten E, Vangerow B. Høibraaten E, et al. Among authors: vangerow b. Tidsskr Nor Laegeforen. 2004 May 20;124(10):1422; author reply 1422-3. Tidsskr Nor Laegeforen. 2004. PMID: 15195189 Free article. Norwegian. No abstract available.
Activated protein C (Xigris): a drug in trouble.
Vangerow B, Mignini MA. Vangerow B, et al. Acta Anaesthesiol Scand. 2007 Feb;51(2):261-2. doi: 10.1111/j.1399-6576.2006.01215.x. Acta Anaesthesiol Scand. 2007. PMID: 17261152 No abstract available.
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Nicholls SJ, Lincoff AM, Barter PJ, Brewer HB, Fox KA, Gibson CM, Grainger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Riesmeyer J, Vangerow B, Ruotolo G, Weerakkody GJ, Nissen SE. Nicholls SJ, et al. Among authors: vangerow b. Am Heart J. 2015 Dec;170(6):1061-9. doi: 10.1016/j.ahj.2015.09.007. Epub 2015 Sep 16. Am Heart J. 2015. PMID: 26678626 Clinical Trial.
Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.
Power TP, Ke X, Zhao Z, Bonine NG, Cziraky MJ, Grabner M, Barron JJ, Quimbo R, Vangerow B, Toth PP. Power TP, et al. Among authors: vangerow b. Vasc Health Risk Manag. 2018 Feb 5;14:23-36. doi: 10.2147/VHRM.S146266. eCollection 2018. Vasc Health Risk Manag. 2018. PMID: 29440909 Free PMC article.
Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial.
Patnaik A, Yap TA, Chung HC, de Miguel MJ, Bang YJ, Lin CC, Su WC, Italiano A, Chow KH, Szpurka AM, Yu D, Zhao Y, Carlsen M, Schmidt S, Vangerow B, Gandhi L, Xu X, Bendell J. Patnaik A, et al. Among authors: vangerow b. Clin Cancer Res. 2021 Mar 1;27(5):1267-1277. doi: 10.1158/1078-0432.CCR-20-2821. Epub 2020 Nov 23. Clin Cancer Res. 2021. PMID: 33229456 Clinical Trial.
30 results